• Sihuan Pharmaceutical’s non-wholly owned unit Xuanzhu Biopharm granted exclusive Thailand commercialisation rights for Bireociclib tablets to Innobic (Asia) and ZaoAn International.
• Deal runs until June 30, 2036; covers import, marketing, sales, distribution; Innobic to lead Thai registration and hold marketing authorisation.
• ZaoAn to act as intermediary with primary payment obligations; Xuanzhu to supply product at agreed prices.
• Agreement includes annual minimum purchase commitments, licence fees payable on signing, plus a payment tied to Thai FDA marketing authorisation.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sihuan Pharmaceutical Holdings Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260903-12318617), on September 03, 2026, and is solely responsible for the information contained therein.